Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Both fecal immunochemical test (FIT) and fecal calprotectin (Fcal) results are useful biomarkers for ulcerative colitis (UC). However, the situations in which each marker should be used are largely unknown. Methods: A total of 110 colonoscopy intervals of UC patients were assessed, and correlations between changes in colonoscopic findings and changes in the two aforementioned fecal markers were examined. Results: Among patients with mucosal healing (MH) and negative FIT or Fcal results at the initial colonoscopy, FIT and Fcal findings exhibited accuracies of 93% (38/41) and 79% (26/33), respectively, for predicting the results of the subsequent examination. Among the 24 patients who showed endoscopic activity at the precedent colonoscopy and MH at the subsequent examination, positive-to-negative conversion of FIT and Fcal findings at the subsequent examination was observed in 92% (12/13) and 62% (8/13) of patients, respectively. Among the 43 patients who showed endoscopic activity at both the precedent and subsequent examinations, Fcal findings reflected the change in endoscopic activity better than FIT results (r=0.59, p<0.0001 vs r=0.30, p=0.054). Conclusions: The FIT is useful for confirming MH and the occurrence of relapse. In contrast, Fcal is useful for monitoring the mucosal status of patients with active inflammation.
Abstract
Background/Aims: Both fecal immunochemical test (FIT) and fecal calprotectin (Fcal) results are useful biomarkers for ulcerative colitis (UC). However, the situations in which each marker should be used are largely unknown. Methods: A total of 110 colonoscopy intervals of UC patients were assessed, and correlations between changes in colonoscopic findings and changes in the two aforementioned fecal markers were examined. Results: Among patients with mucosal healing (MH) and negative FIT or Fcal results at the initial colonoscopy, FIT and Fcal findings exhibited accuracies of 93% (38/41) and 79% (26/33), respectively, for predicting the results of the subsequent examination. Among the 24 patients who showed endoscopic activity at the precedent colonoscopy and MH at the subsequent examination, positive-to-negative conversion of FIT and Fcal findings at the subsequent examination was observed in 92% (12/13) and 62% (8/13) of patients, respectively. Among the 43 patients who showed endoscopic activity at both the precedent and subsequent examinations, Fcal findings reflected the change in endoscopic activity better than FIT results (r=0.59, p<0.0001 vs r=0.30, p=0.054). Conclusions: The FIT is useful for confirming MH and the occurrence of relapse. In contrast, Fcal is useful for monitoring the mucosal status of patients with active inflammation.
참고문헌 (24)
- Podolsky DK, "Inflammatory bowel disease", N Engl J Med, 347, pp.417~429 (2002)[DOI]
- Peyrin-Biroulet L, "Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease", J Crohns Colitis, 5, pp.477~483 (2011)[DOI]
- Schoepfer AM, "Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes", Inflamm Bowel Dis, 15, pp.1851~1858 (2009)[DOI]
- D'Haens G, "Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease", Inflamm Bowel Dis, 18, pp.2218~2224 (2012)[DOI]
- Nakarai A, "Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test", Am J Gastroenterol, 108, pp.83~89 (2013)[DOI]
- Takashima S, "Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test", Am J Gastroenterol, 110, pp.873~880 (2015)[DOI]
- Jun Kato, "Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin?", Intestinal research, 14(1), pp.5~14 (2016), 대한장연구학회
- Schoepfer AM, "Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes", Inflamm Bowel Dis, 19, pp.332~341 (2013)[DOI]
- Mooiweer E, "Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation", Inflamm Bowel Dis, 20, pp.307~314 (2014)[DOI]
- Lobaton T, "A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis", Inflamm Bowel Dis, 19, pp.1034~1042 (2013)[DOI]
- Nancey S, "Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases", Inflamm Bowel Dis, 19, pp.1043~1052 (2013)[DOI]
- D'Inca R, "Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease", Int J Colorectal Dis, 22, pp.429~437 (2007)[DOI]
- Zittan E, "Low Fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn's disease", Inflamm Bowel Dis, 22, pp.623~630 (2016)[DOI]
- Yamaguchi S, "Fecal calprotectin is a clinically relevant biomarker of mucosal healing in patients with quiescent ulcerative colitis", J Gastroenterol Hepatol, 31, pp.93~98 (2016)[DOI]
- Lasson A, "Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis", Inflamm Bowel Dis, 19, pp.576~581 (2013)[DOI]
- De Vos M, "Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy", Inflamm Bowel Dis, 19, pp.2111~2117 (2013)[DOI]
- Jauregui-Amezaga A, "Accuracy of advanced endoscopy and fecal calprotectin for prediction of relapse in ulcerative colitis: a prospective study", Inflamm Bowel Dis, 20, pp.1187~1193 (2014)[DOI]
- Yamamoto T, "Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy", Int J Colorectal Dis, 29, pp.485~491 (2014)[DOI]
- Hiraoka S, "Consecutive measurements by Faecal immunochemical test in quiescent ulcerative colitis patients can detect clinical relapse", J Crohns Colitis, 10, pp.687~694 (2016)[DOI]
- Schroeder KW, "Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study", N Engl J Med, 317, pp.1625~1629 (1987)[DOI]
- Colombel JF, "Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis", Gastroenterology, 141, pp.1194~1201 (2011)[DOI]
- Nakarai A, "Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count", World J Gastroenterol, 20, pp.18367~18374 (2014)[DOI]
- Barreiro-de Acosta M, "Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (Mayo 0 vs 1): a longitudinal cohort study", J Crohns Colitis, 10, pp.13~19 (2016)[DOI]
- Morikawa T, "A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population", Gastroenterology, 129, pp.422~428 (2005)[DOI]